This statement was authored by a group of U.S. pediatric endocrinology leaders with the greatest collective clinical and translational experience administering teplizumab and leading immunotherapy trials for type 1 diabetes. The authors represent diverse academic and clinical programs across the country and include investigators and clinicians most familiar with the implementation, safety monitoring, and real-world delivery of this therapy. Together, they share a unified concern for ensuring patient safety, sustainability, and professional oversight as disease-modifying therapies enter broader clinical practice. Many additional institutions and clinicians who have implemented or supported teplizumab infusion programs share these perspectives and may be added as endorsing centers as this guidance evolves.
